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Abstract
Background: Widely accessible small animal models suitable for the study of hepatitis C virus (HCV) in vivo are lacking,
primarily because rodent hepatocytes cannot be productively infected and because human hepatocytes are not easily
engrafted in immunodeficient mice.
Methodology/Principal Findings: We report here on a novel approach for human hepatocyte engraftment that involves
subcutaneous implantation of primary human fetal hepatoblasts (HFH) within a vascularized rat collagen type I/human
fibronectin (rCI/hFN) gel containing Bcl-2-transduced human umbilical vein endothelial cells (Bcl-2-HUVEC) in severe
combined immunodeficient X beige (SCID/bg) mice. Maturing hepatic epithelial cells in HFH/Bcl-2-HUVEC co-implants
displayed endocytotic activity at the basolateral surface, canalicular microvilli and apical tight junctions between adjacent cells
assessed by transmission electron microscopy. Some primary HFH, but not Huh-7.5 hepatoma cells, appeared to differentiate
towards a cholangiocyte lineage within the gels, based on histological appearance and cytokeratin 7 (CK7) mRNA and protein
expression. Levels of human albumin and hepatic nuclear factor 4a (HNF4a) mRNA expression in gel implants and plasma
human albumin levels in mice engrafted with HFH and Bcl-2-HUVEC were somewhat enhanced by including murine liver-like
basement membrane (mLBM) components and/or hepatocyte growth factor (HGF)-HUVEC within the gel matrix. Following
ex vivo viral adsorption, both HFH/Bcl-2-HUVEC and Huh-7.5/Bcl-2-HUVEC co-implants sustained HCV Jc1 infection for at least
2w e e k sin vivo, based on qRT-PCR and immunoelectron microscopic (IEM) analyses of gel tissue.
Conclusion/Significance: The system described here thus provides the basis for a simple and robust small animal model of
HFH engraftment that is applicable to the study of HCV infections in vivo.
Citation: Harding MJ, Lepus CM, Gibson TF, Shepherd BR, Gerber SA, et al. (2010) An Implantable Vascularized Protein Gel Construct That Supports Human Fetal
Hepatoblast Survival and Infection by Hepatitis C Virus in Mice. PLoS ONE 5(4): e9987. doi:10.1371/journal.pone.0009987
Editor: Jean-Pierre Vartanian, Institut Pasteur, France
Received October 22, 2009; Accepted February 22, 2010; Published April 1, 2010
Copyright:  2010 Harding et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the American Gastroenterology Association (Research Scholar Award to M.J.H.), Section of Comparative Medicine (M.J.H.,
C.M.L.), NIH-R01HL085416 (B.R.S.), NIH-T32AR07107 (S.A.G.), NIH-RO1HL-088258 (A.L.M.B.), NIH-KO1CA107092 (B.D.L.) and NIH-RO1HL62188 (J.S.P.). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: martha.harding@yale.edu
Introduction
Hepatitis C virus (HCV) is a major cause of morbidity and
mortality, resulting in hepatitis, cirrhosis and liver failure,
hepatocellular carcinoma and immune complex vasculitis. Because
HCV replicates efficiently only in human or chimpanzee
hepatocytes, there is no natural small animal model to study
HCV infection in vivo. The most successful mouse model to date
uses albumin promoter-urokinase-type plasminogen activator
(Alb-uPA)-transgenic mice that overexpress uPA in the liver which
results in hypofibrinogenemia, neonatal bleeding and progressive
liver degeneration [1]. Although this defect is lethal in homozy-
gous mice, they can be rescued by transplanting wild-type murine
or human hepatocytes within the first several weeks of life [2,3]. In
the latter system, levels of human hepatocyte chimerism can
develop within the liver parenchyma of engrafted Alb-uPA mice
sufficient to routinely sustain HCV infection for at least 4 months
duration [4–6]. However, the system is difficult to work with since
homozygote uPA mice invariably die as neonates if not engrafted
with wild-type hepatocytes within 2–3 weeks of life [4,5,7].
Furthermore, engrafted Alb-uPA mice harboring high levels
(.50%) of human hepatocytes within the liver parenchyma suffer
from lethal human complement-mediated kidney damage within 3
months of life, if not treated continuously with anti-complement
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human hepatocyte engraftment into healthy adult mice could
significantly expand the accessibility and numbers of mice
available to study human liver diseases, including HCV infections.
We report conditions for the efficient engraftment of human liver
cells at a heterotopic site in adult recipient mice. A subcutaneous
transplantation route was selected because of its simplicity as a
surgical procedure, its provision of ample space for graft expansion
compared to alternate sites, such as under the kidney capsule, and
accessibility of the graft for diagnostic and experimental analyses by
routine biopsy and noninvasive imaging. Transformed hepatoma
cells have been shown to survive following subcutaneous injection in
immunodeficient mice and provide a useful pre-clinical system for
screening novel anti-HCV therapeutic agents [8]. A key character-
istic of tumor cells that distinguishes them from normal cells is their
proclivity to induce angiogenesis, a critical step in tumor
development and growth [9]. Sustained maintenance of primary
human hepatocytes following transplantation at subcutaneous sites
has not yet been realized [10,11]. We reasoned that, in contrast to
hepatoma or other tumor cells, non-transformed hepatocytes are
unable to promote angiogenesis, and as such, unable to induce the
rapid neovascularization required to maintain a normoxic environ-
ment and hence cell viability. Our laboratory has previously shown
that Bcl-2-transduced human umbilical vein endothelial cells (Bcl-2-
HUVEC) are able to form a well-differentiated vascular network
when implanted subcutaneously in protein gels in the severe
combined immunodeficient X beige (SCID/bg) mouse strain [12].
Although this strain is less adept at accepting hematopoietic stem
cell grafts than certain other immunodeficient mice [13], they are
surprisingly superior to these newer strains at accepting vascularized
grafts [14]. The goal of the present study was to utilize such
vascularized gels to support subcutaneous hepatocellular engraft-
ment and HCV infections in vivo.
Methods
Ethics statement
All experimentation in mice was approved by the Yale
University Institutional Animal Care and Use Committee. The
collection and work with HFH was approved by the Institutional
Review Boards of Yale University and Albert Einstein College of
Medicine (AECOM). Following written maternal consent, Human
Fetal Tissue Repository (AECOM hFTR, Dr. Brad Poulos,
Director) staff collected liver tissue from 14–18 week gestational
age abortuses following elective terminations. HUVEC were
harvested from discarded, anonymized umbilical cords with
approval from the Institutional Review Board of Yale University.
The collection of serum from patients with chronic HCV was
approved by the Institutional Review Board of Yale University
and was harvested following written patient consent.
Mice
SCID/bg mice (C.B-17/GbmsTac-SCID/bgN7) were pur-
chased from Taconic (Germantown, New York), housed in
microisolator cages in the Yale Animal Resources Center and
provided free access to autoclaved mouse chow (Harlan, Madison,
WI) and autoclaved, hyperchlorinated water.
HFH cells
Human fetal liver (HFL) tissue was transported to the laboratory
(approximately 1.5 hours travel time) in ice-cold Hanks buffered
salt solution (without calcium and magnesium; Invitrogen,
Carlsbad, CA). HFL tissue was minced into small pieces, then cells
harvested by digesting with 5 mg/ml collagenase type D (Roche,
Indianapolis, IN) in buffer (per 100 ml: 0.39 g NaCl, 0.05 g KCl,
0.24 g HEPES, 0.07 g CaCl2.2H20) at 37uC for 30 minutes with
gentle agitation. Cells were washed in buffer at 50 x g for 5 minutes
then EGTA buffer (5 mM EGTA in Hanks buffered salt solution,
plus 1% BSA, 100 mM Hepes and 14 mM glucose). HFH were
allowed to adsorb to hydrophilic tissue culture plates (Primaria,
Becton Dickinson, San Jose, CA) or rat tail collagen I (rCI)-coated
tissue culture plates (Beckton Dickinson) in Hepatocyte Culture
Medium (HCM), composed of Williams E medium supplemented
with 10 mM nicotimamide, 20 mM HEPES, 17 mM NaHCO3,
11 mg/ml pyruvate, 0.2 mM ascorbic acid, 14 mM glucose, 2 mM
L-glutamine, 10
27 M dexamethasone, 6.26 ug/ml ITS premix
(insulin, transferrin, selenious acid), 1.25 mg/ml bovine serum
albumin, 5.35 mg/ml linoleic acid, 200 units/ml penicillin, 200 mg/
ml streptomycin and 5.0 mg/ml amphotericin B [15]. Fetal calf
serum (FCS; 5%) was added during the initial 24 hour attachment
phase and then serum-containing medium was removed and
replaced with medium containing 20 ng/ml epidermal growth
factor (Invitrogen). Cells were expanded by culturing for up to 1
month with media changes every 2 days. To further expand cell
numbers, cells were passaged by washing cultures twice with
phosphate buffered saline (PBS; pH=7.2), incubating cells with
EGTA buffer for 5–10 minutes at 37uC, then rinsing in collagenase
buffer. Cells were washed in EGTA as described above and flasks
seeded in a 1:2–1:3 ratio or cells used immediately to prepare
vascularized gels, as described below.
Phenotyping of HFL cultures
Passage 1 HFL cells, harvested from a 15 week gestational age
HFL, were grown for 3 days on coverslips coated with 1 mg/ml
rCI (BD Biosciences, San Diego, CA), then fixed with 4%
paraformaldehyde in PBS for 15 minutes at room temperature.
Cells were permeabilized and blocked by treating with PBS
containing 0.1% Tween-20 (PBS-T) plus 1% gelatin (for albumin
detection) or PBS-T plus 1% BSA (for all other intracellular
markers) for 30 minutes at room temperature. Cells were washed
and incubated for 1 hour at room temperature in the above
blocking solutions with the following primary mouse antibodies:
anti-human albumin (Sigma, St. Louis, MO), anti-human
cytokeratin (CK) 8/18 (Abcam, Cambridge, MA), anti-human
CK19 (Chemicon, Temecula, CA), anti-human hepatocyte
(HepPar1; DAKO, Carpinteria, CA), anti-human epithelial-
specific antigen (HEA125; Progen Biotechnik, Heidelberg, Ger-
many), and anti-a-smooth muscle actin (SMA; Novocastra,
Norwell, MA). Alternatively, cells were stained with PE-conjugat-
ed anti-human VE-cadherin (R&D Systems, Minneapolis, MN) or
PE-conjugated anti-human CD31 (Immunotech, Fullerton, CA).
Unconjugated antibodies were detected with Cy3-labelled goat
anti-mouse IgG (H+L) (Jackson ImmunoResearch Laboratories,
West Grove, PA).
Huh-7.5 cells
Huh-7.5 cells were a generous donation from Dr. Charles Rice,
Rockefeller University. Cell cultures were grown on polystyrene
tissue culture plastic-ware in DMEM plus 10% FCS, 2 mM L-
glutamine, non-essential amino acids, 100 units/ml penicillin and
100 mg/ml streptomycin. Cells were passaged by using 0.25%
trypsin/1 mM EDTA (Invitrogen) and seeded at a dilution of 1:2–
1:3, or cells used immediately to prepare vascularized gels, as
described below.
Preparation of retrovirally transduced HUVEC
HUVEC were derived from discarded, anonymized human
tissues as described [16,17]. Cultures were transduced with a
HCV Mouse Model
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University) encoding caspase-resistant Bcl-2 ([18] kindly provided
by Dr. Marie Hardwick, Johns Hopkins School of Public Health,
Baltimore, MD) and generated as described [19]. An additional
retrovirus encoding the deletion variant (i.e. highly active) form of
hepatocyte growth factor (HGF) [20] was prepared by subcloning
the HGF gene from HGF-pcDNA3.1 ([21], a generous donation
from Dr. Youhua Liu, University of Pittsburgh) into LZRS-
pBMN-Z at BamHI and NotI sites, following PCR amplification
of the HGF gene by using the following primers (forward: 59-
AGACATGGATCCATAAGAAAGCGGCCATGTGGGTGAC -
CAAACTCCTG-39;a d d saB a m H Is i t e )a n d( r e v e r s e :5 9-AT-
AGTTTAGCGGCCGCATTCTTATCTATGACTGTGGTACC-
TTATA-39; adds a NotI site). The production of HGF by HGF-
HUVEC in vitro was monitored by using a commercially-available
ELISA kit (BioSource International, Camarillo, CA) and in vitro
bioactivity was studied by using an established MDCK cell serial
dilution scatter assay [22].
Transplantation
To prepare gels, HFH or Huh-7.5 cells and Bcl-2-HUVEC or a
Bcl-2-HUVEC plus HGF-HUVEC mixture were suspended in
rCI – human fibronectin (hFN) gels as previously described [12].
In some experiments, an additional 2.5 mg/ml murine liver-like
basement membrane (mLBM; Cultrex, R&D Systems) originating
from murine Engelbreth-Holm-Swarm (EHS) tumor and consist-
ing of mouse collagen type IV, laminin, enactin and heparin
sulfate proteoglycan, was added to the gel mixture. Each gel was
prepared by using approximately 5610
5 HFH or Huh-7.5 and/or
1610
6 Bcl-2-HUVEC. The suspension was transferred to a 24-
well plate (Becton Dickinson) and allowed to polymerize at 37uC.
Following 18 hours in culture, polymerized gels were implanted in
mice.
One flank of female SCID/bg mice was shaved by using
clippers. Mice were anesthetized with 30% isoflurane in propylene
glycol, disinfected with iodine followed by 70% ethanol, and then
a 2 cm longitudinal incision was made in the dorsal flank and
subcutaneous tissues bluntly dissected to create a subcutaneous
pocket in the ventral abdominal wall. The gel was gently
transferred to the pocket by using a spatula, taking care to place
the gel under the subcutaneous fascia, and the incision closed with
surgical staples. At the time of necropsy, gels were 1) fixed in 4%
paraformaldehyde-PBS for 2–3 hours, then washed and trans-
ferred to saline, prior to paraffin-embedding for H&E (morphol-
ogy) and immunohistochemical staining (see below) staining; or 2)
snap frozen for qRT-PCR analyses as described below.
Whole mount analysis
Immediately after tissue harvest, 262 mm unfixed gel samples
were blocked by using PBS/1% BSA/5% normal mouse and rat
serum on ice for 30 minutes. Fluorescently-labelled mouse anti-
human and rat anti-mouse CD31 monoclonal antibodies (Im-
munotech and BD Biosciences, respectively) were added prior to
incubation with occasional inversion on ice for 2–3 hours. After
washing with PBS, samples were placed on slides and coverslipped
as described [23].
Immunohistochemistry (IHC)
Paraffin-embedded sections (5 mm) were de-paraffinized with
xylene and then re-hydrated in ethanol and water. For antigen
retrieval, sections were subjected to 95uC for 15 minutes in
10 mM sodium citrate buffer, pH=6.0. Sections stained for Bcl-2
(DAKO), CK8/18 (Abcam), CK7 (Santa Cruz Biotechnologies,
Santa Cruz, CA), and CD31 were also treated with 20 mg/ml
proteinase K in 0.1 M Tris, pH 8.0, for 10 minutes at 37uC.
Endogenous peroxidase activity was blocked with 0.3% hydrogen
peroxide in methanol for 15 minutes. Slides were blocked in PBS-
T/5% normal goat serum (blocking buffer for Bcl-2, CK8/18, and
CD31) or PBS-T/5% BSA (blocking buffer for CK7) for 30
minutes at room temperature followed by avidin and biotin
solutions (Vector Laboratories, Burlingame, CA) for 15 minutes
each. Primary antibody (mouse anti-human Bcl-2, mouse anti-
human CK8/18, mouse anti-human CD31, or goat anti-human
CK7) diluted in blocking buffer was added and slides were
incubated overnight at 4uC. After washing in PBS-T, bound
antibody was detected with the appropriate biotin-labelled goat
anti-mouse or donkey anti-goat IgG (H+L) (Jackson ImmunoR-
esearch Laboratories), Vectastain ABC reagent system, and DAB
substrate (Vector Laboratories). Finally, slides were counterstained
with hematoxylin (Sigma).
Transmission electron microscopy
To analyze cultured cells, primary HFH were grown on Primaria
plasticware for 5 days prior to fixation with 2.5% glutaraldehyde in
0.1 M cacodylate buffer, pH 7.4, for 1 hour. Samples were
postfixed for 1 hour in 1% osmium tetroxide in 0.1 M cacodylate
buffer, stained in 2% uranyl acetate in 50 mM maleate buffer, and
dehydrated in ethanol. Ultrathin sections (60 nm) were cut from
epon blocks, stained with 2% uranyl acetate and lead citrate, and
examined in a Tecnai 12 BioTWIN electron microscope (FEI/
Phillips, Hillsboro, Oregon). To analyze gel tissue, 262m mg e l
samples were fixed for 2 hours in freshly-prepared Karnovsky’s
buffer (2.5% glutaraldehyde/2% paraformaldehyde in 0.1 M
cacodylate buffer) and analyzed as described above.
Human protein ELISAs
Human albumin and human a-anti-trypsin levels in the mouse
plasma was confirmed by using human-specific ELISA kits from
Bethyl Laboratories, Montgomery, TX and Alpco Diagnostics Inc.
Salem, NH, respectively, and human HGF levels in supernatants
of in vitro-propagated HGF-HUVEC was determined by using a
human-specific ELISA kit from R&D Systems.
HCV
The cell culture-derived strain of HCV, Jc1, has been previously
described [24,25] and was propagated and titrated on Huh-7.5
[26]. The chimpanzee serum, ‘‘Rodney’’, was a generous gift from
Dr. Kris Krawczynski, Division of Viral Hepatitis, Centers for
Disease Control and Prevention. The patient sera originated from
a chronically-infected individual.
Preparation of HCV-infected HFH/Bcl-2-HUVEC and Huh-
7.5/Bcl-2-HUVEC gels
P0 HFH from a 16 week gestational age liver were expanded in
T75 flasks for 4 days, as described above. HFH were washed once
with HCM and either infected with HCV Jc1, ‘‘Rodney’’ or
‘‘Pat001’’ by using a 6 hour adsorption period with gentle rocking
in HCM plus 2 mg/ml lipid rich albumin (LRA, Albumax I,
Invitrogen) or mock-infected with the same media. Following the
infection period, the inoculum was removed and flasks replenished
with fresh HCM plus 2 mg/ml LRA. Twenty-four hours
following, gels were prepared with HCV-infected and mock-
infected gels and Bcl-2-HUVEC, as described above, and then
implanted in mice. HFH were also grown in Primaria 6 well
plates, infected as described above, and maintained in vitro for up
to 8 days post-infection before detecting HCV by IHC, as
described below.
HCV Mouse Model
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e9987RNA extraction from gel tissue
At 2 weeks post-engraftment, mice were euthanized and
gels retrieved. Tissue slices of 0.560.560.5 cm
3 volume were
immersed in 1 ml RNAlater (Ambion, Austin, TX) overnight at
4uC and then frozen at 280uC. To harvest RNA, the frozen
block of RNAlater/gel was transferred to a foil pocket situated on
a metal block that was pre-chilled by placing on dry ice and then
the gel was retrieved by disrupting the block with a pestle. The
frozen gel slice was transferred to a fresh, pre-chilled foil pocket,
and the gel further disrupted into a powder by using a pestle. The
powder was immediately dissolved in 600 ml RLT buffer, and
incubated at 4uC for 15 minutes with agitation. Solution was
homogenized by centrifuging through a QIAshredder spin
column and then RNA extracted by using an RNeasy kit (both
from Qiagen, Valencia, CA) according to the manufacturer’s
instructions. RNA was eluted from the column with 30 mlR N a s e -
free water, aliquoted into 5 ml volumes and stored at 280uCu n t i l
qRT-PCR analysis.
qRT-PCR
RNA (100 ng/reaction) was amplified by using Brilliant II
SybrGreen kit (Stratagene, La Jolla, CA) by using a 25 ml final
volume in an Opticon cycler (MJ Research, Waltham, MA). The
primers used in the current study are described in Table 1. Cycle
conditions were as follows: 50uC for 30 minutes (RT) then 95uC
for 10 minutes (RT denaturation), followed by 40 cycles of 95uC, 1
minute; 48uC, 1 minute; 60uC, 1 minute; and 72uC, 1 minute.
Data were normalized by using GAPDH expression as internal
controls, or in the case of HCV infections, expressed as threshold
cycles (Ct).
HCV immunocytochemistry and immunoelectron
microscopy
HCV Jc1- and mock-infected HFH cultures were prepared as
described above, and then maintained in vitro for various times
post-infection. HCV replication was determined by staining for the
HCV non-structural (NS) protein NS5A, as previously described
[26]. Briefly, cells were fixed in methanol at 220uC for 10
minutes. Following 2 washes with PBS, endogenous peroxidases
were quenched with 3% hydrogen peroxide in methanol for 15
minutes at room temperature. Cells were blocked for 30 minutes at
room temperature with blocking buffer consisting of PBS/T
containing 1% BSA and 0.2% dried skim milk. Cells were
incubated with anti-NS5A mouse monoclonal antibody (clone
9E10 [27], provided by Dr. Charles Rice, final concentration of
40 ng/ml,) for 60 minutes at room temperature. Following 2
washes with PBS, horse radish peroxidase-labelled anti-mouse IgG
(ImmPress, Vector Laboratories) was allowed to react for 30
minutes at room temperature. Following 2 additional washes with
PBS and 1 wash with PBS-T, DAB (DAKO) was added and color
allowed to develop for 1–10 minutes. Cells were counter-stained
with hematoxylin.
HCV replication was detected in tissue sections by staining
for the HCV NS5A by IEM. Briefly, ultrathin 70 nm sections
were cut on a Leica FC6 Cryoultramicrotome and collected on
formvar/carbon coated grids as previously described [28]. Grids
were placed section side down on drops of 0.1 M ammonium
chloride for 10 minutes to quench untreated aldehyde groups,
then blocked for non-specific binding in 1% fish skin gelatin
(FSG) in PBS for 10 minutes. Following extensive washing in
PBS, grids were incubated with mouse monoclonal antibody
against HCV NS5A (clone 9E10, 1:500 dilution in 1% FSG/
PBS) for 30 minutes. After additional washes, grids were
incubated with a bridging rabbit anti-mouse serum (Jackson
ImmunoResearch Laboratories, Inc; 1:200 in 1% FSG/PBS) for
30 minutes, rinsed and incubated on protein A gold-10 nm
beads (University Medical Center, Utrecht, Netherlands; 1:75
dilution in 1% FSG/PBS). Grids were washed, fixed by using
1% glutaraldehyde/PBS for 5 minutes, rinsed again, transferred
to a methyl cellulose/0.5% uranyl acetate mixture for 10
minutes, and then dried. Samples were viewed at 80 Kv with a
FEI Tecnai Biotwin election microscope and images recorded
by using a Morada CCD and iTEM (Olympus, Center Valley,
PA) software.
Results
In vitro characterization of cultured HFH
Cells harvested from 15-16 week gestational age human fetuses
were attached to Primaria tissue culture plates in the presence of
5% FCS for 4–6 hours, then cultured in chemically-defined
medium (HCM) in the absence of serum. The cells initially
attached as clumps (Fig. 1A) but over the next 3–5 days (Fig. 1B
and 1C) spread to form regions of polygonal cells with round
nuclei and prominent nucleoli, surrounded by a monolayer of
stromal cells (Fig. 1C, box). Relatively wide intercellular spaces
(Fig. 1C, arrows) resembling epithelial canalicular surfaces were
frequently observed. Examination by transmission electron
microscopy (TEM) revealed features consistent with healthy and
functionally active hepatic epithelial cells in day 7 primary
cultures. Specifically, the presence of normal multivesicular bodies
and nuclei (Fig. 1D, box and arrow, respectively), desmosomes and
mitochondria (Fig.1E, box and arrow, respectively), and canalic-
ular villi and tight junctions (Fig. 1F, box) indicated the presence of
healthy hepatocytes through at least 1 week of culture when
maintained on cationic plates in HCM. The polygonal cells
present in cell clumps were likely bipotential HFH—which
normally develop into either mature hepatocytes or cholangiocytes
in vivo—as judged by their consistent co-expression of 1) albumin
Table 1. Primers used for qRT-PCR analyses.
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progenitors, 2) HEA125 and CK19 (Fig. 2D and 2E), expressed in
cholangiocytes and their progenitors, and 3) CK8/18, expressed in
both cell types (Fig. 2B). Some elongated cells expressed the stellate
cell or the vascular smooth muscle cell marker SMA (Fig. 2F). A
few spindle-shaped cells expressed the endothelial cell (EC) marker
CD31, and yet even fewer cells of the same morphology expressed
VE-cadherin (Fig. 2G and 2H, respectively). Cells stained with
secondary antibody alone are shown in Fig. 2I, as a negative
control. The HFH cultures could be passaged twice with EGTA/
collagenase treatment; however, at passage 3 or later, the
proportion of polygonal epithelial-appearing cells declined,
presumably due to overgrowth by stromal cells. Passage 0 and 1
HFH cultures consistently produced high levels of albumin (i.e.
.300 ng/ml media/24 hours).
Morphologic features of gels containing HFH following in
vivo engraftment
Simple rCI-hFN gels containing HFH cultures only (i.e. without
Bcl-2-HUVEC) were prepared and then incubated for 18 hours in
vitro prior to transfer to a subcutaneous pocket in SCID/bg mice.
At both 2 and 4 weeks following transplantation, all gels were
46362m m
3 in size (data not shown). Three of 4 and 2 of 3 HFH
gels appeared to be vascularized based on hematoxylin and eosin
(H&E)-stained tissue sections at 2 and 4 weeks post-engraftment,
respectively. Specifically, vascularized gels contained an average of
12.9 and 4.7 recognizable vessels per 406field at 2 and 4 weeks
post-engraftment, respectively (Fig. 3A). Though vessels of
capillary size (,10 mm) were found in vascularized HFH grafts
at both 2 and 4 weeks post-engraftment, vessels were significantly
larger (p,0.05; with the largest vessel being 22.2 mm) at the latter
time point (Fig. 3B). Nevertheless, the grafts did not appear to be
highly perfused at either time point as judged by general pallor.
Because CD31+ EC were observed in the HFH cultures prior to
gel formation and implantation (Fig. 2G), we analyzed whether
vessels in HFH grafts were donor (human)- or host (mouse)-
derived. In vitro analysis of pre-implantation HFH gels confirmed
the presence of tubes (Fig. S1A, arrows), possibly indicative of early
vessel formation and a potential donor contribution to the
observed microvascular network. Human- and mouse-specific
CD31 immunostaining of unfixed HFH gels at harvest confirmed
that vessels were largely of donor origin: an elaborate trabecular
network of human CD31-lined tubes comprised the bulk of the gel
(Fig. S1B) while larger vessels positive for mouse CD31 were
infrequently observed and confined to the gel periphery (Fig. S1C;
arrow demarcates gel edge). Capillaries present in HFH gels at 2
weeks post-engraftment (Fig. S1D, arrows) were lined with human
CD31-expressing cells based on IHC staining (Fig. S1E). Even
though vascularized HFH grafts appeared poorly perfused based
on a lack of red blood cells (RBC) in H&E-stained sections at 4
weeks post-engraftment, some RBC-filled capillaries were identi-
fied by TEM analysis (Fig. S1F, arrows).
Implant cellularity appeared to correlate with the degree of
vascularity. In more vascularized gels, a proportion of the extra-
vascular cells were identified as unorganized hepatic epithelial cells
based on their expression of CK8/18 by IHC (Fig. 4A).
Specifically, the average number of CK8/18+ cells at 2 weeks
post-engraftment was 10.8 +/2 3.6 per high-power field. Some
hepatic epithelial cells staining intensely positive for CK8/18 self-
organized, forming putative bile ducts (Fig. 4B and 4C,
micrograph and top IHC insets) that occasionally possessed a
lumen (Fig. 4C). These structures also stained positive for CK7, a
Figure 1. Morphologic analysis of cultured HFH. Phase contrast micrographs (A–C) show primary cell cultures on days 1 (A), 3 (B), and 5 (C)
following initial harvest. Panel C also demonstrates the heterogeneity of the cultured cell population, consisting of large regions of polygonal
epithelial cells with adjacent bile canaliculi (black arrows) and spindle-shaped intervening stromal cells (box region). Electron micrographs (D–F) of
day 7 cultures confirm the presence of HFH with normal ultrastructural features. D: multivesicular bodies and nuclei (box and arrow, respectively); E:
desmosomes and mitochondria (box and arrow, respectively); F: canalicular villi and tight junctions (box). Size bars: 100 mm (A–C); 1 mm (D–F).
doi:10.1371/journal.pone.0009987.g001
HCV Mouse Model
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hepatocytes (Fig. 4C, bottom inset). TEM analysis revealed
hepatoblast-like epithelial cells (Fig. 4D and 4E) containing
prominent round nuclei and cytosol rich in rough endoplasmic
reticulum (Fig. 4D, arrows), mitochondria (Fig. 4E, arrow), and
occasional lipid droplets (Fig. 4E, box). Although ‘‘canalicular’’
regions limited by tight junctions were observed (Fig. 4D, box), the
lack of microvilli within the non-expanded ‘‘canalicular’’ space
suggested an immature phenotype. Quiescent stellate cells,
characterized by their star-shaped morphology and large intra-
cellular lipid droplets (Fig. 4F, box), were also noted by TEM.
Morphologic features of gels containing HFH/Bcl-2-
HUVEC following in vivo engraftment
Previous studies have shown that a mature microvasculature
network develops and is maintained for at least 2 months following
engraftment of Bcl-2-HUVEC in rCI-hFN gels when placed
within the abdominal wall of SCID/bg mice [12,17]. We therefore
tested whether engraftment and viability of HFH at ectopic sites
would increase when co-transplanted with Bcl-2-HUVEC. Vessel
density was significantly lower in the HFH and HFH/Bcl-2-
HUVEC gels at both 2 and 4 weeks post-engraftment compared to
grafts containing Bcl-2-HUVEC alone (Fig. 3A; p,0.001). In
other words, co-engraftment with HFH appeared to inhibit vessel
formation by Bcl-2-HUVEC. At the same time, compared to gels
containing Bcl-2-HUVEC or HFH alone, co-transplants of Bcl-2-
HUVEC and HFH in simple rCI-hFN gels were consistently
larger (66463m m
3) and, compared to HFH alone, appeared
much more well-perfused by gross observation (Fig. S2A). Vessel
diameters were significantly smaller in HFH implants compared to
Bcl-2-HUVEC gels at 2 weeks post-engraftment only (7.0 +/2 0.4
versus 12.3 +/2 1.6 mm; Fig. 3B, p,0.01). Although the average
vessel size did not significantly differ between the Bcl-2-HUVEC
and the HFH/Bcl-2-HUVEC co-engrafted gels at 4 weeks post-
engraftment (Fig. 3B; 9.8 mm versus 9.1 mm), multi-layered vessels
were more frequently observed in the HFH/Bcl-2-HUVEC co-
seeded gels (Fig. S2B) compared to the Bcl-2-HUVEC implants
(Fig. S2C) at both time points. Staining for human and mouse
CD31 revealed a developed human microvascular network in the
center of the gel (Fig. S2D and S2E) surrounded by mature,
investing murine vessels at the gel edge (Fig. S2F). Based on IHC,
Figure 2. Immunofluorescence staining analysis of HFH. HFH were harvested from 15 week gestational age HFL tissue and cultured on
collagen type I-coated coverslips for 8 days in chemically-defined HCM. Cells were fixed with 4% paraformaldehyde and permeabilized and blocked
with either PBS-T plus 1% gelatin (albumin detection) or PBS-T plus 1% BSA (for all other intracellular or cell surface markers). DAPI was also added to
identify cell nuclei. The cultures were stained for albumin (A), CK8/18 (B), HepPar1 (C), HEA125 (D), CK19 (E), SMA (F), CD31 (G), or VE-cadherin (H).
Unconjugated primary antibodies (all except CD31-PE and VE-cadherin-PE) were detected with a Cy3-labelled anti-mouse secondary antibody. HFH
stained with secondary antibody alone served as a negative control (I). Photos were captured at a 63x magnification on a Zeiss fluorescence
microscope using OpenLab Imaging Software (Improvision, Waltham, MA). Size bar indicates 15 mm.
doi:10.1371/journal.pone.0009987.g002
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EC, whereas larger vessels contained mouse CD31+ EC or a
combination of human CD31+ and mouse CD31+ EC (data not
shown). TEM analyses did not reveal intercellular or intracellular
fenestrations between EC, typical of sinusoidal endothelium, in
either HFH or HFH/Bcl-2-HUVEC grafts.
At 4 weeks post-engraftment, the total number of extra-vascular
cells within the gel stroma was significantly higher in the HFH/
Bcl-2-HUVEC gels (333.9 +/2 18.0) compared to the additive
numbers of extra-vascular cells in the Bcl-2-HUVEC gels (85.6 +/
2 11.4) and HFH gels (162.7 +/2 14.4; see Fig. 3C). This same
effect was not observed at 2 weeks, suggesting that increased vessel
numbers promoted HFH expansion and survival. Consistent with
our original hypothesis that inadequate perfusion limits the growth
and survival of non-transformed heptocytes following implanta-
tion, significantly greater numbers of hepatic epithelial cells were
observed in HFH/Bcl-2-HUVEC grafts compared to HFH grafts
based on CK8/18 staining (Fig. 5A). Specifically, an average of
37.2 and 10.8 CK8/18+ cells were observed per 406 field at 2
weeks post-engraftment, representing 13.5% and 5.9% of the
extra-vascular cell pool in HFH/Bcl-2-HUVEC gels and HFH
gels, respectively. At 4 weeks post-engraftment, some of the CK8/
18+ cells appeared to associate in structures resembling paren-
chymal cords (Fig. 5B). The presence of HFH and/or more
mature hepatocytes in HFH/Bcl-2-HUVEC grafts was confirmed
by TEM analyses (Fig. 5C-5E). Immature HFH were identified
based on the oval shape of the nucleus (Fig. 5C) and wide, under-
developed Golgi cisternae (Fig. 5C, arrow). Maturing, active
hepatocytes were identified by round nuclear morphology (Fig. 5D
and 5E), presence of tight junctions between adjacent cells, apical
canalicular microvilli (Fig. 5D, boxed regions and arrows,
respectively), and characteristic apical membrane region contain-
ing coated pits and pericanalicular vesicles (Fig. 5E, asterisk).
Epithelial cells were also noted to organize into rudimentary
ductules by TEM in HFH/Bcl-2-HUVEC grafts (Fig. 5F).
Analysis of representative Bcl-2-HUVEC, HFH, and HFH/Bcl-
2-HUVEC gels confirmed a cell viability of .97% based on
TUNEL assay (data not shown).
HFH function following engraftment in gels in
immunodeficient mice
Passage 0 and 1 HFH cultures consistently produced high levels
of albumin prior to engraftment (i.e. .300 ng/ml media/
24 hours) and low levels of human albumin were present in the
plasma of immunodeficient mice harboring grafts of HFH/Bcl-2-
HUVEC. Specifically, an average of 19.6 ng/ml albumin was
detected in the plasma of mice engrafted with our base model of
HFH/Bcl-2-HUVEC suspended within a rCI/hFN protein gel
(Fig. 6, left bar). However, mice engrafted with human hepatoma
Figure 3. Quantitative analysis of vessel and extra-vascular cell numbers in gels incorporating Bcl-2-HUVEC and/or HFH. Panels A-C
show vessel density and size (A and B, respectively) and number of extra-vascular cells (C) calculated from H&E-stained sections of vascularized gels
harvested at 2 and 4 weeks post-engraftment. Results are expressed as the mean 6 standard error of the mean (SEM) and asterisks indicate
significance at p#0.05. Panels D–F show representative H&E-stained micrographs from gels harvested at 4 weeks post-engraftment containing Bcl-2-
HUVEC (D), HFH (E), and HFH/Bcl-2-HUVEC (F). Size bar: 100 mm.
doi:10.1371/journal.pone.0009987.g003
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high human albumin levels (390 ng/ml plasma; Fig. 6, right bar,
p,0.001). Therefore, it appeared that while the non-transformed,
bipotential HFH were surviving, a large proportion might be
undergoing de-differentiation and/or progression towards a
differentiated cholangiocyte upon engraftment, based on plasma
albumin levels.
Strategies to promote and preserve HFH function
We therefore tested additional approaches designed to maintain
more HFH in a differentiated state within vascularized gels: 1)
both Bcl-2-HUVEC and HGF-HUVEC were included within the
gel; 2) additional mLBM, including mouse laminin, collagen type
IV and heparin sulfate proteoglycans were added to the protein
gel; and 3) both strategies were combined. Prior to engraftment,
we confirmed that HGF-transduced HUVEC secreted 10 ng/ml
HGF into the supernatant and exhibited appropriate bioactivity in
an MDCK cell-based scatter assay (Fig. S3). Slightly higher (but
statistically insignificant) increases in human albumin (i.e. to
40 ng/ml) were detected in the plasma of mice engrafted with Bcl-
2- and HGF-HUVEC or in gels containing mLBM (Fig. 6, middle
bars). No additional increases were noted if both conditions were
included within the same protein gel. Histological analyses
revealed that HFH appeared as clusters of columnar epithelial
cells that were organizing into duct-like structures in gels prepared
by using all 4 protocols: Bcl-2-HUVEC and rCI/hFN, Bcl-2-
HUVEC and rCI/hFN/mLBM, Bcl-2+HGF-HUVEC and rCI/
hFN, and Bcl-2+HGF-HUVEC and rCI/hFN/mLBM (Fig. 7A–
7D, respectively, white arrows) by 2 weeks post-engraftment.
Intriguingly, one structural difference was noted in the HFH/EC
interactions within the various treatment groups. Specifically, in
gels containing mLBM, the HFH clusters were surrounded with
multiple layers of EC (white box in Fig. 7B and 7D). TEM analyses
confirmed the presence of a Disse-like space containing matrix
proteins between the HFH and EC (Fig. 7E and 7F, box).
However, the underlying EC did not appear to contain
fenestrations characteristic of true hepatic sinusoids. We then
analyzed expression of several liver-specific genes within the gel
implant, specifically human albumin (expressed by both HFH and
more mature hepatocytes), huma hepatic nuclear factor 4a
(HNH4a; expressed in differentiated hepatocytes) and human
CK7 (found in mature cholangiocytes). The expression of albumin
mRNA was slightly higher in the Bcl-2+HGF-HUVEC and
mLBM groups compared to Bcl-2-HUVEC/rCI/hFN group
(Fig. 7G, GAPDH ratio of 0.65 versus 0.60), whereas HNF4a
expression was higher in all 3 treatment groups (Fig. 7H, GAPDH
ratio of .0.73 in Bcl-2-HUVEC and rCI/hFN/mLBM, Bcl-
2+HGF-HUVEC and rCI/hFN, and Bcl-2+HGF-HUVEC and
rCI/hFN/mLBM groups) compared to the base Bcl-2-HUVEC
and rCI/hFN group (GAPDH ratio of 0.66). Intriguingly, even
though levels of albumin expression were lower in all types of
HFH gels compared to the Huh 7.5 gel (Fig. 7G), HNH4a
expression in the HFH gels containing additional mLBM, HGF-
HUVEC or both components (Fig. 7H) approached levels found in
the Huh-7.5 gel, perhaps indicating that some HFH were
maintained in a differentiated state. However, CK7 was also
mildly increased (ie. Fig. 7I, GAPDH ratio of .0.88 in Bcl-2-
HUVEC and rCI/hFN/mLBM, Bcl-2+HGF-HUVEC and rCI/
Figure 4. Morphology of gels containing passage 1 HFH implanted at an ectopic site. A: H&E-stained section from a graft harvested at 2
weeks post-engraftment showed the presence of RBC-filled capillaries and a duct-like structure lined with columnar epithelial cells that stain intensely
positive for CK8/18 (inset). B. At 4 weeks post-engraftment, a small proportion of the unorganized extra-vascular cells within the HFH gel stroma
stained positive for CK8/18. Staining was absent in similarly-stained Bcl-2-HUVEC alone gels. C: H&E-stained sections from a graft harvested at 4 weeks
post-engraftment showed a duct with a lumen that stains intensely for CK8/18 (top inset) and CK7 (bottom inset). D, E: TEM analyses identified
metabolically active HFH possessing extensive rough endoplasmic reticulum (D, arrows), tight junctions (D, box) with an immature intervening
canalicular region, phenotypically normal mitochondria (E, arrow), and lipid droplets (E, box). F: Quiescent stellate cells harboring numerous large fat
droplets (box) were also observed. Size bars: 10 mm (A-C), 2 mm (D, E), and 1 mm (F).
doi:10.1371/journal.pone.0009987.g004
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versus a ratio of 0.8 in Bcl-2-HUVEC and rCI/hFN group).
Therefore, it appeared that some cells were differentiating towards
a cholangiocyte phenotype. None of the aforementioned changes
in HFH gene expression amongst the various treatment groups
were pronounced. Huh-7.5 cells continued to express high levels of
albumin and HNF4a and low levels of CK7 in vivo (Fig. 7G-7I).
HGF expression was highest in gels containing additional mLBM
(Fig. 7J).
Replication of HCV Jc1 infection in HFH in HFH/Bcl-2-
HUVEC gels in vivo
Following confirmation of long-term survival of HFH within
Bcl-2-HUVEC gels, we next studied whether engrafted HFH
would support infection of the tissue tropic HCV Jc1 isolate in vivo.
In a preliminary experiment, we confirmed that low percentages of
HFH indeed sustained a HCV Jc1 infection in vitro.A ta
multiplicity of infection of 1, in vitro HFH cultures consistently
become infected with HCV Jc1, based on HCV NS5A+ cells.
Specifically, immunostaining for HCV NS5A revealed that ,1i n
10,000 cells supported HCV Jc1 replication at days 4 and 8 post-
infection (Fig. 8A and 8B, respectively; representative positive-
stained HFH shown at the black arrows). In contrast, neither
NS5A+ cells nor HCV RNA in the culture medium were observed
in HFH cultures adsorbed with serum originating from a
chronically-infected human or chimpanzee (data not shown).
Next, total RNA from gel tissue containing non-infected and Jc1-
infected HFH (representatives highlighted with black arrows in
Fig. 8C and 8D, respectively) was extracted and subjected to HCV
qRT-PCR. HCV RNA was detected in both HFH/Bcl-2-
Figure 5. Morphology of gels containing passage 1 HFH/Bcl-2-HUVEC implanted at an ectopic site. Many extra-vascular cells in the HFH/
Bcl-2-HUVEC gels harvested at 2 weeks post-engraftment stained positive for CK8/18 (A) and appeared more organized by 4 weeks post-engraftment
(B). Immature HFH, characterized by their oval cell and nuclear shape, few mitochondria, and wide, undeveloped Golgi (C, arrow) were confirmed by
TEM. More mature hepatic epithelial cells (D, E; Hep) possessed characteristic large circular nuclei and bile canaliculi (box) with apical microvilli
(arrows). Areas of clathrin-coated pits and coated vesicles indicated endocytic activity at the canalicular membrane surface (E, asterisk). Columnar
epithelial cells were shown to organize into rudimentary ductules (F). Size bars: 100 mm (A), 10 mm (B, F), 1 mm (C, D), and 0.5 mm (E).
doi:10.1371/journal.pone.0009987.g005
Figure 6. Quantitation of human albumin in the plasma of
engrafted mice. Human albumin (20 ng/ml) was detected in the
plasma of mice co-engrafted 2 weeks earlier with HFH and Bcl-2-HUVEC
suspended in rat tail collagen I (rCI) and human fibronectin (hFN) (left
bar). The albumin concentration increased to 40 ng/ml when gels also
contained murine liver-like basement membrane (mLBM) proteins or
HGF-transduced HUVEC, however no further increases in albumin
secretion were observed by using a combination of mLBM plus HGF-
HUVEC (middle bars). Highest levels of albumin (average of 392 ng/ml)
were observed in mice harboring Huh-7.5/Bcl-2-HUVEC gels (right bar).
Data is expressed as ng/ml human albumin in mouse plasma +/2 S.E.M.
doi:10.1371/journal.pone.0009987.g006
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tissue, but not from RNA extracts originating from a non-infected
gel (Fig. 8E), nor in gels infected ex vivo with serum from a
chronically infected chimpanzee or human patient (data not
shown). In a follow-up infection experiment, HCV RNA was not
detected in infected HFH/Bcl-2-HUVEC (n=0/2) cast in rCI/
hFN proteins, however was present in a matched gel prepared
with additional HGF-HUVEC and mLBM (Fig. 8F, n=2/2).
Epithelial cells were maintained in both non-infected and infected
HFH/Bcl-2-HUVEC and Huh-7.5/Bcl-2-HUVEC grafts
(Fig. 9A–9D) for the duration of the in vivo culture period based
on H&E staining. Furthermore, no phenotypic changes were
apparent between the mock- and virus-infected HFH or Huh-7.5
gels, based on gross or histological observations (Fig. 9A versus 9C
and Fig. 9B versus 9D). The presence of HCV replication was
determined by using IEM methods specific for HCV NS5A.
Immunogold background stain was only rarely observed in non-
infected HFH and Huh-7.5 gel tissue (Fig. 9E and 9F). In contrast,
immunogold staining was observed in both HFH and Huh-7.5
(Fig. 9G–9J, black arrows), confirming that both epithelial cell
types supported HCV Jc1 replication in vivo. Similar to our qRT-
PCR analyses, the number of infected cells and amount of NS5A
per cell was higher in the Huh-7.5 gel, compared to the HFH gel
(Fig. 9H and 9G, respectively). NS5A staining was typically
associated with ER membranes (Fig. 9J, white arrow).
Discussion
We report here on the development of a simple model of
primary human hepatoblast and hepatoma cell engraftment and
HCV infection in healthy, adult immunodeficient mice. We chose
to use HFH, rather than human adult hepatocytes, for several
reasons: 1) these cells are routinely available thus well-suited for
scheduled transplantation experiments; 2) HFH may be expanded
in vitro by using conditions that maintain typical hepatocytic
morphology and gene expression patterns even after several
months of culture [15]; 3) HFH may be transduced with
lentiviruses in vitro [29,30]; and 4) HFH may be combined with
hematopoietic stem cell (HSC) co-engraftment from the same
human fetal liver [13,31] to investigate the development of an
immunocompetent mouse model for studies of HCV pathogenesis
and pre-clinical testing of prophylactic and therapeutic HCV
vaccines. Despite encouraging successes of high levels of rodent
hepatoblast expansion within the liver parenchyma of immuno-
deficient mice [32–34], similar degrees of liver reconstitution have
not been achieved following transplantation of early human liver
progenitors [29,35–39]. Therefore, it appears that the murine liver
environment lacks the appropriate signals for HFH maturation
and/or expansion within the liver parenchyma. The use of
subcutaneous implants of HFH or even earlier progenitors, such as
hepatocyte-like cells derived from human embryonic stem cells
[40,41], circumvents the endogenous murine liver environment
and allows for the rational design of a matrix that can sustain large
number of HFH that are infectable with HCV.
One possible reason for the limited prior successes of the
heterotopic approach for hepatic epithelial cell transplantation is
that cell survival is hampered by the lack of rapid neovascular-
ization to support graft perfusion [42–44]. A delay in thorough
vascularization of the implant area creates an environment low in
oxygen and other nutrients and likely contributes to the initial
death of transplanted cells [45]. In general, cells positioned more
than 200 mm from a blood vessel suffer from hypoxia and die [46],
and cell death is especially significant for cells with high metabolic
activity, such as hepatocytes [42]. Sustained-release microspheres
containing angiogenic factors promote enhanced short-term (up to
2 weeks) vascularization and rodent hepatocyte viability [47–52].
We report here that the vasculature present in the HFH/Bcl-2-
HUVEC gels supported higher numbers of CK8/18+ hepatic
Figure 7. Effect of mLBM and/or HGF-HUVEC on morphology and gene expression in vascularized gels containing HFH. A–D: At 2
weeks post-engraftment, large clusters of HFH (white arrows) were observed in gels containing HFH, Bcl-2-HUVEC and rCI/hFN alone (A), or with
additional mLBM (B), additional HGF-HUVEC (C), or additional mLBM and HGF-HUVEC (D). HFH clusters were surrounded by multiple layers of
endothelial cells when cast in gels containing mLBM (white boxes in B and D). E–F: TEM analyses confirmed the presence of a Disse-like space in vivo,
bordered by HFH and endothelial cells and containing matrix proteins (letter D, H, and E, respectively, in panels E and F and letter M in panel F). Size
bars: 10 mm (A–D), 2 mm (E), and 500 nm (F). G–I: Analysis of mRNA expression in gel tissue revealed loss of hepatocyte phenotype in HFH-containing
gels, based on lower levels of albumin (G) and HNF4a (H), and higher levels of CK7 (I), compared to Huh-7.5-containing gels. Albumin and HNFa
expression (G and H, respectively) was slightly better maintained by inclusion of LBM and/or HGF-HUVEC. The presence of continued HGF expression
in vivo was confirmed by HGF qRT-PCR (J) and most prominent in gels containing mLBM. Data in panels G–I is expressed as a ratio of target gene
mRNA to GAPDH mRNA internal control.
doi:10.1371/journal.pone.0009987.g007
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PLoS ONE | www.plosone.org 10 April 2010 | Volume 5 | Issue 4 | e9987Figure 8. In vitro and in vivo maintenance of HCV Jc1 infection in HFH. A, B: IHC staining for HCV NS5A revealed rare positive HFH at day 4
and day 8 post-infection (arrows in A and B, respectively). Similarly stained mock-infected HFH cultures confirmed the specificity of the HCV NS5A IHC
assay (B, inset). C, D: Mock- or HCV Jc1-infected HFH cells were co-engrafted with Bcl-2-HUVEC and a rCI/hFN matrix on the abdominal wall of SCID/bg
mice (C and D, respectively). Representative gels harvested at 2 weeks post-engraftment are highlighted by black arrows. E, F: qRT-PCR analysis
revealed the presence of HCV RNA in Jc1-infected HFH gels (E, middle column), but not in mock-infected gels (E, left column). Analysis of mRNA
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of oxygen and other nutrients delivered by blood perfusion.
Alternatively, direct EC-hepatocyte contact or paracrine signaling
may have facilitated hepatocyte survival and development
[53–55].
We noted that the inclusion of either mLBM or HGF-
transduced HUVEC supported increased production of human
albumin by engrafted HFH and as well sustained higher levels of
HCV Jc1 replication. Systemic administration of HGF in normal
and liver-injured mice [56,57] and rats [58] caused a hepato-
trophic effect that altered liver-associated serum biochemistries. A
deletion variant of HGF, lacking 5 consecutive amino acids from
the kringle domain, results in higher mitogenic activity in rat
hepatocytes compared to full-length HGF [59] and provides
additional protective effects for hepatocyte transplantation in liver
injury models [60]. A further benefit of systemic delivery of HGF
in our studies stems from the fact that HGF also enhances VEGF-
induced angiogenesis [61] and prevents EC apoptosis [62]. Liver
matrix proteins, produced mainly by resident hepatic stellate cells
[63,64], provide structural and behavioral support for epithelial
cells and EC. Liver matrix proteins consist of typical basement
membrane components (laminins 1–4, nidogen, enactin, heparin
sulfate proteoglycans and type IV collagen), and also includes the
non-basement membrane constituents type I collagen and
fibronectin [65,66]. Interactions between the hepatocyte and its
unique basement membrane are important for maintaining
hepatocyte survival and differentiated function [66,67]. In fact,
changes in the liver protein matrix, such as the loss of the a4 and
a6 isoforms of type IV collagen [68], are hypothesized to
contribute to decreased hepatocyte viability during the progression
of liver cirrhosis [66,69,70]. A laminin-rich matrix has recently
been shown to promote differentiation of mouse fetal hepatoblasts
both in vitro and in vivo [71], supporting our findings of higher levels
of albumin production when HFH are cast in gels with a mLBM.
Furthermore, it is possible that co-engrafted human stellate cells
produce a typical liver matrix within the gel stroma that may help
to support hepatocyte survival in addition to the normoxic
environment provided by Bcl-2-HUVEC and fetal liver-derived
EC [51].
The levels of HCV RNA detected in the gel parenchyma were
higher in Huh-7.5-containing gels compared to those seeded with
HFH. The Huh-7.5 hepatoma subline is highly permissive for
HCV full length and subgenomic replicons, including those
derived from HCV type 1b [72] as well as engineered cell culture
tropic HCV type 2a [27,73]. In contrast, neither human nor
chimpanzee-derived natural isolates identified to date can be
propagated in Huh-7.5 cells. The presence of neutralizing
antibodies in these serum-derived HCV sources complicates use
of these strains, and is a possible explanation for the lack of
detection following in vitro infection of HFH in our study. The lack
of antibody in cell culture-derived virus, and the ability to infect
with a specific cell culture titer, highlights several advantages of
Jc1-based HCV systems. However, some patient sera isolates of
HCV have been identified can that replicate in HFH [74–76].
Such samples are typically derived from acutely infected patients,
prior to the development of antibody. These types of materials are
rare and we do not have access to such samples.
We believe that ours is the first report of cell culture tropic virus
infection of HFH. We observed association of NS5A with ER
membranes in infected cells, which was anticipated from prior
IEM studies following in vitro infection of Huh7 cells with JFH-1
virus [77]. However, even though human albumin was detectable
in the plasma of Huh-7.5 gel-engrafted mice, HCV RNA was
below the limit of detection (.10
4 copies/ml) in plasma harvested
extracted from HCV Jc1-infected Huh-7.5-containing gel tissue was used as a positive control (E, right column). Increased levels of HCV Jc1 RNA were
detected in gels containing additional HGF-HUVEC and mLBM, compared to the Bcl-2-HUVEC and rCI/hFN gel system (F, right versus left column,
respectively). Data points represent individual gels.
doi:10.1371/journal.pone.0009987.g008
Figure 9. Histological and IEM analysis of HCV Jc1-infected HFH and Huh-7.5. Large numbers of epithelial-appearing cells were observed in
Bcl-2-HUVEC gels harvested at 2 weeks post-engraftment and containing either mock-infected HFH or Huh-7.5 cells (A and B, respectively) or HCV
Jc1-infected HFH or Huh-7.5 (C and D, respectively). Staining for HCV NS5A by IEM revealed minimal background stain in both mock-infected HFH
and Huh-7.5 (E and F, respectively), in contrast to the presence of HCV NS5A protein immunogold stain associated with ER membranes observed in
infected HFH and Huh-7.5 gels (G and H, respectively, black arrows). Panels I and J are higher magnifications of infected HFH and Huh-7.5 cells within
the gels. White arrow in J indicates ER membrane. Size bars: 20 mm (A–D), 1 mm (E, F), 500 nm (G, H), and 100 nm (I, J).
doi:10.1371/journal.pone.0009987.g009
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and release in vitro [76], and one would expect the same within the
described gel system in vivo. Increasing the initial size and cell
density of the graft should enhance HCV titers such that they are
detectable from plasma samples using qRT-PCR or Huh-7.5-
based cell culture. As an adjunct, novel imaging techniques could
be considered for real-time monitoring of even low levels of HCV
infection within grafts without the need to harvest gel tissue [8].
Intriguingly, we have also been able to detect in vitro replication of
HCV Jc1 in neonatal, but not adult, hepatocytes [Harding et al.,
AJP, submitted].
In conclusion, we have characterized a non-injury trans-
plantation strategy in which cultured HFH or human
hepatoma cells are engrafted at a subcutaneous site in
commercially-available adult SCID/bg mice. Consistent with
our hypothesis that inadequate perfusion is a limiting factor for
HFH engraftment, higher levels of epithelial cells survived at
least 8 weeks post-engraftment within gels that were vascular-
ized by Bcl-2-transduced HUVEC. Following ex vivo exposure,
both HFH and Huh-7.5 cells sustained HCV Jc1 infection for
at least 2 weeks in vivo, and was expected to continue for at
least 2 months, given the duration of HFH survival within
vascularized gels. We believe that our findings represent the
first reported success of maintaining HFH on the abdominal
wall of immunodeficient mice. This novel system represents a
simple small animal model of human primary hepatic
epithelial or hepatoma cell engraftment, which should offer
new opportunities for studying HCV infections and therapeu-
tics in vivo. Future work directed at promoting hepatocellular
differentiation and proliferation, and confirmation of Jc1 HCV
infection following injections, would serve to further increase
the utility of the model.
Supporting Information
Figure S1 Characterization of neovascularization of passage 1
HFH gels. Tubes were observed forming in vitro within 15 hours of
HFH gel preparation (A, arrows). A trabecular network of small
tubes was observed in gels stained with human-specific CD31
antibody (B), whereas mouse-specific CD31-lined vessels were
rarely observed and limited to the gel periphery (C; gel edge is
demarcated with arrow). Capillaries were observed in H&E-
stained sections (D, arrows) and were determined to be of human
origin by virtue of their human CD31 expression (E, arrow). TEM
analysis confirmed the presence of morphologically normal
capillaries (F, arrow) containing RBC within the gel stroma. Size
bars: 100 mm (A), 15 mm (B, C), 10 mm (D, E), and 5 mm (F).
Found at: doi:10.1371/journal.pone.0009987.s001 (0.79 MB
TIF)
Figure S2 Characterization of neovascularization of passage 1
HFH/Bcl-2-HUVEC gels. At 4 weeks post-engraftment, HFH/
Bcl-2-HUVEC gels were 66463 mm3 in size (A) and contained
large, multi-layer arterioles (B, arrows) that were not present in
matched Bcl-2-HUVEC gels (C). The majority of vessels in the
HFH/Bcl-2-HUVEC grafts originated from Bcl-2-HUVEC based
on Bcl-2-staining of paraffin-embedded gel tissue (D). The total
contribution of donor (human) and host (mouse) vessels within the
gel based on human and mouse CD31-staining of unfixed gel
sections is shown in E and F, respectively. Size bars: 1 mm (A),
10 mm (B–D), and 15 mm (E, F).
Found at: doi:10.1371/journal.pone.0009987.s002 (1.02 MB TIF)
Figure S3 HGF-transduced HUVEC produce bioactive HGF in
vitro. Conditioned medium (CM; 1:50 dilution) from various
cultures of transduced HUVEC were added to MDCK cells and
then representative individual colonies (shown at 0 hr, panels A–
D) were tracked for changes in morphology at 24 hours (panels E–
H). Note the higher rate of cell proliferation and spreading
(‘‘scatter’’) at 24 hr following the addition of CM in cultures
exposed to Bcl-2/HGF-HUVEC CM (H), compared to media
alone (E), HUVEC (F) and Bcl-2-HUVEC (G) CM.
Found at: doi:10.1371/journal.pone.0009987.s003 (0.30 MB TIF)
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